These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 9159603)

  • 1. The problem of compliance to cholesterol altering therapy.
    Insull W
    J Intern Med; 1997 Apr; 241(4):317-25. PubMed ID: 9159603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The therapeutic gap--compliance with medication and guidelines.
    Feely J
    Atherosclerosis; 1999 Sep; 147 Suppl 1():S31-7. PubMed ID: 10575060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in cardiovascular risk factors by combined pharmacological and nonpharmacological strategies: the main results of the CELL Study.
    Lindholm LH; Ekbom T; Dash C; Isacsson A; Scherstén B
    J Intern Med; 1996 Jul; 240(1):13-22. PubMed ID: 8708586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factor modification: rationale for management of dyslipidemia.
    Gotto AM
    Am J Med; 1998 Feb; 104(2A):6S-8S. PubMed ID: 9550500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adherence to National Cholesterol Education Program Treatment goals in postmenopausal women with heart disease. The Heart and Estrogen/Progestin Replacement Study (HERS). The HERS Research Group.
    Schrott HG; Bittner V; Vittinghoff E; Herrington DM; Hulley S
    JAMA; 1997 Apr 23-30; 277(16):1281-6. PubMed ID: 9109465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Value of determining serum cholesterol levels in patients with coronary heart disease].
    Stalenhoef AF
    Ned Tijdschr Geneeskd; 1997 Dec; 141(52):2545-8. PubMed ID: 9555153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cholesterol lowering after participation in the Scandinavian Simvastatin Survival Study (4S) in Finland.
    Strandberg TE; Lehto S; Pyörälä K; Kesäniemi A; Oksa H
    Eur Heart J; 1997 Nov; 18(11):1725-7. PubMed ID: 9402446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of pharmacist intervention and patient education on lipid-lowering medication compliance and plasma cholesterol levels.
    Ali F; Laurin MY; Larivière C; Tremblay D; Cloutier D
    Can J Clin Pharmacol; 2003; 10(3):101-6. PubMed ID: 14506507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Achieving National Cholesterol Education Program goals for low-density lipoprotein cholesterol in cardiac patients: importance of diet, exercise, weight control, and drug therapy.
    Allison TG; Squires RW; Johnson BD; Gau GT
    Mayo Clin Proc; 1999 May; 74(5):466-73. PubMed ID: 10319076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cholesterol management in high-risk patients without heart disease. When is lipid-lowering medication warranted for primary prevention?
    Grundy SM
    Postgrad Med; 1998 Nov; 104(5):117-20, 123-4, 129. PubMed ID: 9823389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term changes of serum cholesterol with cholesterol-altering drugs in patients with coronary heart disease. Veterans Administration Drug-Lipid Cooperative Study.
    Detre KM; Shaw L
    Circulation; 1974 Nov; 50(5):998-1005. PubMed ID: 4609636
    [No Abstract]   [Full Text] [Related]  

  • 12. Primary care practice adherence to National Cholesterol Education Program guidelines for patients with coronary heart disease.
    McBride P; Schrott HG; Plane MB; Underbakke G; Brown RL
    Arch Intern Med; 1998 Jun; 158(11):1238-44. PubMed ID: 9625403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cholesterol management in the era of managed care.
    Grundy SM
    Am J Cardiol; 2000 Feb; 85(3A):3A-9A. PubMed ID: 10695701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statins in the prevention of coronary heart disease.
    Williamson DR; Pharand C
    Pharmacotherapy; 1998; 18(2):242-54. PubMed ID: 9545143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cholesterol lowering in the elderly population. Coordinating Committee of the National Cholesterol Education Program.
    Grundy SM; Cleeman JI; Rifkind BM; Kuller LH
    Arch Intern Med; 1999 Aug 9-23; 159(15):1670-8. PubMed ID: 10448768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lessons from cholesterol-lowering trials.
    Smith SC
    Am J Med; 1998 Jun; 104(6A):28S-32S. PubMed ID: 9684849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Electronic monitoring of compliance to lipid-lowering therapy in clinical practice.
    Schwed A; Fallab CL; Burnier M; Waeber B; Kappenberger L; Burnand B; Darioli R
    J Clin Pharmacol; 1999 Apr; 39(4):402-9. PubMed ID: 10197299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of statins in acute coronary syndromes: managing the unmet need.
    Jackson G
    Int J Clin Pract; 2000 Sep; 54(7):445-9. PubMed ID: 11070569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poor compliance: the hidden risk factor.
    LaRosa JC
    Curr Atheroscler Rep; 2000 Jan; 2(1):1-4. PubMed ID: 11122718
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical prevention of coronary heart disease through cholesterol-lowering therapy.
    Grundy SM
    Curr Ther Endocrinol Metab; 1997; 6():520-6. PubMed ID: 9174799
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.